What records are connected here?
- Evidence lanes
- 1
- Source years
- 1
- Drugs@FDA applications
- 1
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved1,2,3Evidence: Large human trialsMetabolic and weight
Also called Langlara1
Insulin glargine-aldy is a long-acting insulin, sold as Langlara, that FDA licensed on April 29, 2026 to improve blood-sugar control in adults and children with diabetes.1,2,3 Its label states that Langlara is biosimilar to Lantus (insulin glargine), meaning it was approved on data showing it is highly similar to Lantus with no clinically meaningful differences.1 The clinical trials in its label are the insulin glargine trials against NPH insulin, which the Lantus label describes as trials of Lantus. No trial run with insulin glargine-aldy itself is described in the sources reviewed here.1,4
| What it is | A long-acting insulin glargine product that its label states is biosimilar to Lantus. The label states that insulin lowers blood sugar by helping muscle and fat take up glucose and by reducing the liver’s glucose output.1 |
|---|---|
| FDA status | FDA-approved. Drugs@FDA lists Langlara, application BLA761412, with an approval date of April 29, 2026. The cited label has no boxed warning.1,2 |
| Human evidence | Large randomized trials of Lantus, the reference product, compared with NPH insulin. The Langlara label summarizes them as insulin glargine studies; they are not trials of insulin glargine-aldy.1,4 |
| Evidence strength | Large randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned |
Insulin glargine-aldy is an insulin glargine product, a lab-made long-acting form of insulin. Drugs@FDA lists it as Langlara, from Sunshine Lake Pharma, under application BLA761412.1,2
FDA’s approval letter states that the application was submitted under section 351(k) of the Public Health Service Act and describes it as seeking licensure as biosimilar to and interchangeable with US-licensed Lantus.3
The Langlara label states that it is biosimilar to Lantus, and explains that a biosimilar is approved on data showing it is highly similar to an FDA-approved reference product with no clinically meaningful differences.1
The label states that the main action of insulin, including insulin glargine products, is to regulate glucose metabolism.1
According to the label, insulin lowers blood sugar by stimulating glucose uptake, especially by muscle and fat, and by reducing glucose production by the liver.1
The Langlara label summarizes open-label, randomized trials that compared insulin glargine with NPH insulin in 2,327 adults and 349 children with type 1 diabetes and 1,563 adults with type 2 diabetes.1
The Lantus label describes the same trials, with the same numbers, as trials of Lantus. They are the reference product’s trials, not trials of insulin glargine-aldy.1,4
In general, the reduction in HbA1c, a measure of long-term blood sugar, with insulin glargine was similar to that with NPH insulin, according to both labels.1,4
Evidence-strength label: Large randomized human trials. How this label is assigned
Yes. Drugs@FDA lists Langlara, application BLA761412, with an approval date of April 29, 2026.2
FDA’s approval letter licenses Langlara and states that it is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.3
The Langlara label cited here (DailyMed SPL version 5, published July 8, 2026) states the same indication, states that Langlara is biosimilar to Lantus, and states that it is not recommended for treating diabetic ketoacidosis.1
The label has no boxed warning. It states that the product is contraindicated during episodes of low blood sugar and in people allergic to any insulin glargine product or its ingredients.1
Its warnings cover low or high blood sugar after changes in insulin treatment, low blood sugar including from medication errors, allergic reactions, low potassium, and fluid retention and heart failure when used with PPAR-gamma agonists.1
The data behind FDA’s decision: Drugs@FDA lists no review documents for this application, and the approval letter does not set out its findings.2,3
Whether FDA found Langlara interchangeable with Lantus: the approval letter says the application sought that, but the label cited here states only that it is biosimilar.1,3
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Insulin glargine-aldy: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Insulin glargine-aldy are the records PeptideScanner has selected and published, not every registration or paper about Insulin glargine-aldy. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.
Evidence summary
FDA-approved as Langlara. Its label states that it is biosimilar to Lantus. The trials in the label are the insulin glargine trials against NPH insulin, which the Lantus label describes as trials of Lantus; no trial of insulin glargine-aldy itself is described in the sources reviewed here.↗↗↗↗
Status sources checked through July 22, 2026. See status sources and coverage →
Langlara · Read September 15, 2026 · Preserved label summary 1
The cited Langlara label covers glycemic control in adults and children with diabetes mellitus. It does not cover treatment of diabetic ketoacidosis. Label: 1 ↗
Section 14 summarizes open-label randomized comparisons of insulin glargine with NPH insulin involving 2,327 adults and 349 children with type 1 diabetes and 1,563 adults with type 2 diabetes. HbA1c reductions were generally similar. These are the label’s insulin-glargine clinical studies, not a count of trials conducted specifically with insulin glargine-aldy. Label: 14.1, 14.2, 14.3 ↗
The label describes potentially life-threatening hypoglycemia, severe hypersensitivity, low potassium, medication errors and fluid retention or heart failure with thiazolidinediones. Hypoglycemia episodes and relevant hypersensitivity are contraindications. Label: 4, 5 ↗
U.S. product labeling hosted by the National Library of Medicine. This account concerns this product and label edition; other formulations and jurisdictions require their own records.
LANGLARA (insulin glargine-aldy) injection, solution · SPL version 5 · published 2026-07-08
Label ZIP SHA-256: c393585bbdb741f3ff47b5db3b45ed1dfc84a10d2d03e83796d8aae94d3ad187. Extracted XML SHA-256: a785c2958a54aeb8984fecab009a9c899d5b73479104b4d2ae4982ac6f32f770.
This account summarizes the cited product label. A separate appraisal of the complete clinical literature and other jurisdictions remains open.
Reviewed 2026-09-19 · Preserved version 1
FDA’s April 2026 letter licenses Langlara, insulin glargine-aldy, under BLA 761412. The reference product is US-Lantus; this should not be confused with other insulin-glargine suffixes or applications. FDA PDF pp. 1 ↗
The letter addresses the specified Langlara presentation as biosimilar to and interchangeable with the specified US-Lantus presentation. It is not a ranking of all insulin products or permission to treat their presentations as identical. FDA PDF pp. 1 ↗
This approval letter records a licensing decision and the glycemic-control indication. It does not supply a trial-level comparative efficacy analysis; the separate label account explains which insulin-glargine studies its label summarizes. FDA PDF pp. 1 ↗
Read the separate U.S. label account → Label version and indication scope are preserved there; these agency reviews describe their own dated evidence.
Selected sections read in 1 of 1 inventoried documents; 0 not yet reviewed. Reading selected sections does not establish complete appraisal of a document.
One selected official document from the retained EMA document inventory or an independently retrieved FDA application package. Other formulations, later variations, national records and the wider source inventory remain outside this reading. EMA inventory source ↗
Page references use one-based PDF file pages, which can differ from printed page numbers. Candidate feed associations are not verified application identities.
Selected sections reviewed · fda-langlara-approval-2026 · Document/feed date: 2026-04-29
Application identity and document date were checked in the PDF, independently of the URL year or candidate feed association.
Verified: Langlara · BLA 761412 · Document dated 2026-04-29. Identity checked on PDF pp. 1, 6.
Approval-letter identity, licensing language and signature date only. This is not a clinical-review or trial-level appraisal.
Retrieved 2026-09-19. Read PDF pages: 1, 6 of 6. SHA-256: ef59f1e69d9b3f9045e067d76c1c602dac9f20ab90520c2e7535832db50ab5dc.
Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.
Open machine-readable coverage and record decisions →
Scoped peptide/product-name PubMed query. The aldy-specific query does not search the full parent insulin glargine literature.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
aldy[All Fields] AND insulin[All Fields]
Retrieved 2026-09-15T11:07:09.030685+00:00 · HTTP 200 · SHA-256 1e01cb15bf53366528ed59074e9f9113c824ed986d99842df0a81b323fa1e6e3.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.
1 retrieved · 1 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
products.active_ingredients.name:"INSULIN GLARGINE-ALDY"
Retrieved 2026-09-15T11:10:16.355362+00:00 · HTTP 200 · SHA-256 9d9b9554d36dad7859e00002365c43768fc72d347d3226e47be96c436e4ab0fb.
Showing 1 of 1 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Case-insensitive word-boundary identity terms: ["Insulin glargine-aldy", "Langlara"]
Retrieved 2026-09-15T08:34:22.905972+00:00 · HTTP 200 · SHA-256 a947c2b8a56ac2b92ec96156843f262f5e516f83b375d6791d67a8f6dc695729.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Case-insensitive word-boundary identity terms: ["Insulin glargine-aldy", "Langlara"]
Retrieved 2026-09-15T08:34:29.167460+00:00 · HTTP 200 · SHA-256 c0c68d7d77783e0355cbc75bdd04772e9acc163236fc68abcd794477c4c3d439.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Case-insensitive word-boundary identity terms: ["Insulin glargine-aldy", "Langlara"]
Retrieved 2026-09-15T08:34:31.262344+00:00 · HTTP 200 · SHA-256 7448bf4e77e3345b3f3fbb7062c335d2302d8ea458a246bbe8256ce48aad2806.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
"Insulin glargine-aldy" OR "Langlara"
Retrieved 2026-09-15T11:26:14.448759+00:00 · HTTP 200 · SHA-256 b54968c05ff881a1ef7ce604b6a340248f8e2aee8637bef06da0f5693f520df8.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
Living status brief
FDA-approved as Langlara. Its label states that it is biosimilar to Lantus. The trials in the label are the insulin glargine trials against NPH insulin, which the Lantus label describes as trials of Lantus; no trial of insulin glargine-aldy itself is described in the sources reviewed here.↗↗↗↗
The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Regulatory · source date October 19, 2026
Insulin glargine-aldy DailyMed SPL version 7↗Added to PeptideScanner November 15, 2026Regulatory · added November 15, 2026
Insulin glargine-aldy DailyMed SPL version 7↗Source date October 19, 2026Regulatory · added November 15, 2026
Insulin glargine-aldy DailyMed SPL version 6↗Source date September 21, 2026Regulatory · added August 22, 2026
Insulin glargine-aldy DailyMed SPL version 5↗Source date July 8, 2026PeptideScanner currently has no selected clinical trial records, PubMed literature metadata records, and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
0 of 0 selected trial records include at least one phase value; 0 of 0 include a status value in the retained structured contract.
0 of 0 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
We now state that the label calls Langlara biosimilar to Lantus, and that the trials in its label are the reference product’s trials, which the Lantus label describes as trials of Lantus. We also no longer suggest that an unread page of the approval letter might hold FDA’s findings: it does not.
DailyMed lists Structured Product Labeling version 6 for the reviewed Insulin glargine-aldy label family with a published date of 2026-09-21. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 7 for the reviewed Insulin glargine-aldy label family with a published date of 2026-10-19. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Original-submission application metadata connected by exact reviewed active-ingredient names.
Version metadata and exact historical ZIP receipts for the reviewed label family, without reproducing or interpreting label text.
Selected records span April 29, 2026 to October 19, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Regulatory
DailyMed lists Structured Product Labeling version 7 for the reviewed Insulin glargine-aldy label family with a published date of 2026-10-19. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗
Regulatory
DailyMed lists Structured Product Labeling version 6 for the reviewed Insulin glargine-aldy label family with a published date of 2026-09-21. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗
Regulatory
DailyMed lists Structured Product Labeling version 5 for the reviewed Insulin glargine-aldy label family with a published date of 2026-07-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗
Regulatory
DailyMed lists Structured Product Labeling version 2 for the reviewed Insulin glargine-aldy label family with a published date of 2026-06-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗
Regulatory
DailyMed lists Structured Product Labeling version 1 for the reviewed Insulin glargine-aldy label family with a published date of 2026-06-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for BLA 761412 with status AP dated 2026-04-29, and names insulin glargine-aldy among the application record's active ingredients.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026